CLS board appoints Dan Mogren as acting CEO when Lars-Erik Eriksson resigns at his own request
Clinical Laserthermia System AB (publ) (CLS) announces the board’s decision to appoint Dan Mogren as acting CEO for the company, as Lars-Erik Eriksson, who has been the company’s CEO from its start in 2006, leaves his assignment at his own request. Dan Mogren has been Chief Commercial Officer in CLS since 2014 and, among other things, responsible for the company’s U.S. operations. Lars-Erik Eriksson will continue to be part of CLS’ executive management as Chief Financial Officer.
– First of all I’d like direct my warmest thanks to Lars-Erik for his work as CEO of CLS. He has meant a lot for the company’s development since the start in 2006, and he will continue to work for CLS’ success in his role as CFO and board member, says Hans von Celsing, chariman of the board in CLS. I’m very pleased that Dan Mogren will take over as acting CEO. Mogren knows the company well, which is a condition for not losing pace in our ongoing activities, as well in product development as commercially, says von Celsing.
– The company is in a strategically exciting phase and after more than ten years as CEO it feels as the right time to hand over this assignment to a new resource. I’m happy to see that Dan Mogren steps in as acting CEO, which guarantees a smooth transition. I will continue to work operationally as CFO, a task that I so far has combined with being CEO, but that now can get the focus required for the company’s development, says Lars-Erik Eriksson, departing CEO and co-founder of CLS.
– I’m looking forward to take over as acting CEO of CLS and continue to develop the company in line with the choices of paths and important decisions that are in front of us, commercially, clinically and in product development, says Dan Mogren, Chief Commercial Officer of CLS, soon acting CEO in CLS.
Dan Mogren has 20 years’ experience from management positions in business and product development, marketing and sales. Dan Mogren has founded and developed several companies in different medtech areas. Dan Mogren will start his new assignment as acting CEO on 1 December 2020.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
T: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG® |Thermal Therapy System including specially designed sterile disposable products for the minimally invasive treatment of cancerous tumors, in accordance with regulatory approvals in EU and USA. The products are marketed for image-guided laser ablation (FLA, LITT) and for treatment with imILT®, the company’s interstitial thermotherapy with a potentially immune stimulating effect. CLS is headquartered in Lund, Sweden and has subsidiaries in Germany and Irvine, CA. CLS is listed Nasdaq First North Growth Market under the ticker CLS B. Certified Adviser (CA) is FNCA Sweden AB, Ph: +46 8 528 00 399. E-mail: info@fnca.se. Further information is available on www.clinicallaser.se.
The TRANBERG®|Thermal Therapy System has not yet received market clearance for immune stimulating interstitial laser thermotherapy (imILT®) or its Thermoguide thermometry software by the Food and Drug Administration (FDA) in the United States of America (USA).